-
Regulatory March 18, 2025Vivesto licenses Apealea to China’s Zhida Pharmaceutical
-
Non Regulatory January 16, 2025Vivesto receives approval to initiate a dose-finding study of Paccal Vet in cats
-
Non Regulatory December 19, 2024Vivesto strengthens Cantrixil program with new preclinical results and patent application
Vivesto published its Q4 report for 2024 on February 20, 2025, at 08.00 am CET.